Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Current Liabilities (2016 - 2026)

Cytosorbents filings provide 16 years of Total Current Liabilities readings, the most recent being $9.7 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 1.18% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a 1.18% decrease, with the full-year FY2025 number at $9.7 million, down 1.18% from a year prior.
  • Total Current Liabilities hit $9.7 million in Q4 2025 for Cytosorbents, down from $10.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $14.7 million in Q1 2022 to a low of $8.3 million in Q3 2024.
  • Median Total Current Liabilities over the past 5 years was $10.0 million (2023), compared with a mean of $10.8 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 36.22% in 2021 and later surged 50.34% in 2022.
  • Cytosorbents' Total Current Liabilities stood at $13.7 million in 2021, then decreased by 29.04% to $9.7 million in 2022, then soared by 44.48% to $14.0 million in 2023, then dropped by 30.0% to $9.8 million in 2024, then fell by 1.18% to $9.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $9.7 million (Q4 2025), $10.1 million (Q3 2025), and $9.8 million (Q2 2025) per Business Quant data.